Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Banyu Warned about Payment to Doctors Attending Januvia Seminars
October 4, 2010
- Canagliflozin Significantly Reduces HbA1c, Weight in PIIb
October 4, 2010
- Takeda Launches Dexilant in Canada
October 4, 2010
- EMA Recommends Suspension, US FDA Restricts Access to Avandia
October 4, 2010
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Emerging Countries Drive Global Drug Industry: Ms Chui of IMS
September 27, 2010
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
- Rozerem Ranked No. 1 in Both HP, GP Markets: RepTrack Survey
September 27, 2010
- Korosho Confirms “Principle of Nondiscrimination”for Generics Applied by Indian Firms
September 27, 2010
- Ritsuo Hosokawa Appointed New Health Minister
September 27, 2010
- Taiyo, Kyowa Should Be More Severely Punished: Nichibyokyo
September 27, 2010
- Bendamustine Launched in Singapore: SymBio, Eisai
September 27, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…